Related Experiment Video
Updated: Jul 19, 2026
08:34
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
[Radiobiologic basis for using 131I to treat patients with thyroid cancer].
R Suwiński1, M Gawkowska-Suwińska
1Centrum Onkologii-Instytut im. M. Skłodowskiej-Curie, Oddział w Gliwicach.
Wiadomosci Lekarskie (Warsaw, Poland : 1960)
|August 17, 2002
Summary
Radioiodine (131I) therapy for thyroid cancer relies on tumor cells absorbing iodine. Optimizing treatment involves understanding radiobiology factors like radiosensitivity and exploring novel strategies for better patient outcomes.
Area of Science:
- Nuclear medicine
- Oncology
- Radiobiology
Context:
- Thyroid cancer treatment utilizes radioactive iodine (131I) based on the principle of iodine uptake by differentiated tumor cells.
- The efficacy of 131I therapy depends on radioiodine activity, tumor uptake, and absorbed radiation dose.
Purpose:
- To review the fundamental radiobiological principles governing 131I therapy for thyroid cancer.
- To discuss the factors influencing treatment effectiveness and explore potential improvements.
Summary:
- 131I therapy targets well-differentiated thyroid cancer cells that actively absorb iodine.
- Key factors include 131I's physical properties (half-life, beta decay energy), administered activity, tumor's iodine-avid nature, and total absorbed dose.
- The 'five Rs' of radiobiology (radiosensitivity, repair, redistribution, reoxygenation, repopulation) are crucial biological determinants.
- Investigational strategies like unconventional fractionation or combining 131I with external beam radiation show potential but require further research.
Impact:
- Highlights the need for enhanced research in clinical and experimental radiobiology to refine 131I treatment protocols.
- Suggests that a deeper understanding of radiobiological factors can lead to improved therapeutic strategies for thyroid cancer.
- Emphasizes the ongoing need for better-designed studies to clarify the clinical utility of novel 131I treatment approaches.
More Related Videos
Related Concept Videos
01:28Isotopes and Radioisotopes
In the early 1900s, English chemist Frederick Soddy realized that an element could have atoms with different masses that were chemically indistinguishable. These different types are called isotopes — atoms of the same element that differ in mass. Isotopes differ in mass because they have different numbers of neutrons but are chemically identical because they have the same number of protons. Soddy was awarded the Nobel Prize in Chemistry in 1921 for this discovery.
An isotope containing more...
An isotope containing more...
01:20Synthesis and Regulation of Thyroid Hormones
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...
01:25Imaging Studies II: Positron Emission Tomography and Scintigraphy
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
Fundamental Principles of PET
01:27Hyperthyroidism II: Pathophysiology
Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
01:28Graves' Disease I: Introduction
Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence in...
01:24Graves Disease II: Pathophysiology
Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...